Journal of AdvancedMedical and Dental Sciences Research

Background: Anemia is a prevalent complication of chronic kidney disease, and the interconnection between hematopoiesis (the process of blood cell formation) and the kidneys was initially acknowledged by Richard Bright in 1835. He identified the link between anemia and chronic renal failure. A substantial portion of the health issues experienced by patients with renal failure can be attributed to the complications arising from chronic anemia, underscoring the importance of managing anemia as part of their overall care. Methods: This study was conducted. Study Period was for 2 years who are on haemodialysis for duration of six months to two years. For this a total number of 92 participants were screened. All 92 patients were given erythropoietin [EPOFIT] manufactured by INTAS pharmaceuticals by subcutaneous route. Results: During the course of the study, patients will undergo a series of laboratory investigations at specific time points. At the beginning of the study and at its conclusion, assessments will be made for parameters including hemoglobin (Hb), hematocrit (Hct), reticulocyte count, red blood cell (RBC) counts, serum ferritin levels, and transferrin saturation (TSAT). Conclusion: Out of the 92 patients included in the study, a majority of 62 patients responded to the regular conventional dose of 50 units/kg/dose of erythropoietin, while a smaller subset of 18 patients required an increased dose of 75 units/kg to achieve the target hemoglobin level. The study's findings demonstrated a progressive increase in hemoglobin levels, with 77% of patients showing improvement after 4 weeks of treatment. However, at the end of the 12-week study period, 23% of patients still had not reached the target hemoglobin level, suggesting varying responses to the treatment among the patient population.